Cerus Initiates Phase I Clinical Trial For INTERCEPT Red Blood Cell System
Nov 27th 2008Drug InformationBlood
Cerus Corporation (NASDAQ:CERS) announced today that it has initiated a Phase I clinical trial of its INTERCEPT Blood System for red blood cells. Developed to improve the safety of red blood cell transfusions, the system is designed to inactivate pathogens that may be present in donated red blood cells, while preserving the blood products’ therapeutic properties.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
